Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp ulmonary hypertension (PH), defined as a mean pulmonary arterial pressure (PAP) greater than 25 mmHg at rest, 1,2 is a fatal disease caused by small pulmonary artery obstruction related to vascular proliferation and remodeling. 3 PH is characterized by markedly elevated PAP and increased pulmonary vascular resistance (PVR), frequently leading to right-sided heart failure and death. 3 The pathological changes of the pulmonary arteries in PH include endothelial injury, proliferation and hypercontraction of vascular smooth muscle cells and migration of inflammatory cells. 4,5 Although several vasodilators, anticoagulant agents and lung transplantation are currently used for the treatment of PH, more effective treatment needs to be developed. 6 Identification of prognostic factors is useful for better management of PH. Possibilities include functional class, exercise capacity (eg, 6-min walking distance, cardiopulmonary exercise testing), pulmonary hemodynamics (eg, mean right atrial pressure (RAP), PVR, right ventricular enddiastolic pressure (RVEDP)), right ventricular function (eg, cardiac output (CO), clinical evidence of right ventricular failure), and plasma levels of brain natriuretic peptide (BNP), endothelin-1, uric acid, and troponin. 1,2,7-10 Among these prognostic factors, plasma BNP levels and CO are considered to be the most influential. 11 We closely follow our PH patients every 6-12 months, which includes cardiac catheterization, with the aim of identify new prognostic factors of PH. Here we report that we were able to identify that normalization of CO in response to the therapy is a significant prognostic factor of PH and probably has more significance than BNP.
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secutive PH patients admitted to hospital between 1974 and 2008.
Study Population
The 136 patients had PH of various etiologies, including idiopathic pulmonary arterial hypertension (IPAH, n=43), heritable PAH (n=3), PAH associated with connective tissue diseases (n=21), congenital heart diseases (n=22), or portal hypertension (n=10), pulmonary veno-occlusive disease (n= 4), and PH because of chronic thromboembolism (CTEPH, n=33) ( Table 1) . Besides their regular follow-up, we hospitalize patients if their symptoms or right-heart failure worsen.
Diagnosis of PH
We performed right-heart catheterization in all 136 patients, among whom we were able to perform follow-up catheterization in 88. PH was defined as a mean PAP greater than 25 mmHg at rest. 1,2 Connective tissue disease and liver disease were diagnosed clinically and by blood tests. Congenital heart disease was diagnosed by echocardiography, and CTEPH was diagnosed by ventilation -perfusion RI scans and computed tomography (CT). Pulmonary function tests, arterial blood gases, chest X-ray and CT scan were used to diagnose lung disease and hypoxia. If the aforementioned abnormalities were ruled out, the patients were diagnosed as having IPAH. 2, 5 Heritable PAH was diagnosed as IPAH with a family history of PAH. 2,5,12
Data Collection
Baseline demographic information (including age, sex, height and body weight), clinical diagnosis, comorbidities (connective tissue diseases, liver diseases, congenital heart diseases, and thyroid dysfunction) and hemodynamic data obtained during catheterization were recorded for each patient. Hyperthyroidism was defined as either an elevated level of free triiodothyronine (T3 ≥4.12 pg/ml) and/or thyroxin (T4 ≥1.5ng/dl) or reduced level of thyroid-stimulating hormone (TSH ≤0.46 μIU/ml). Hypothyroidism was defined as either elevated TSH (>3.73 μIU/ml) or a reduced level of free T3 (<2.51 pg/ml) and/or T4 (<0.88 ng/dl). Hemodynamic parameters examined included pulmonary capillary wedge pressure, pulmonary artery pressure (PAP), RVEDP, RAP, CO, cardiac index (CI), systolic and diastolic blood pressures, mean blood pressure, PVR, systolic vascular resistance, and mixed venous oxygen saturation (SV • O2). Lung transplantation and death were defined as cardiopulmonary death. The CI response was evaluated at diagnosis and 1 year after treatment.
Current Medical Treatment of PH
We usually begin oral prostacyclin at a starting dose of 60 mg/day and increase it in a stepwise manner up to 240 mg/day, if tolerable. In daily practice, we usually start intravenous prostacyclin (epoprostenol) therapy during hospitalization at 0.5-1 ng · kg -1 · min -1 , which is carefully increased in a step-wise manner on the basis of symptoms and sideeffects of the drug ( Figure S1 ). Similarly, we usually start bosentan at 31.25 mg/day combined with dobutamine and/or milrinone in PH patients with heart failure, and at 62.5 mg/day in those without heart failure, and then carefully increase the dose in a stepwise manner every week ( Figure S2 ). Regarding sildenafil, we usually start at 30 mg/day and increase the dose up to 60 mg/day if patients can tolerate it. Currently, we treat patients with PH using prostacyclin, bosentan, sildenafil as monotherapies or in combination.
Statistical Analysis
Results are expressed as mean ± SEM. Unpaired t-test was used for comparison of continuous variables and chi-test for categorical variables. Survival from all-cause death and from lung transplantation was estimated by Kaplan-Meier method and differences between the curves were examined for significance using the log-rank test. Univariate and multivariate Cox proportional hazard models were used to estimate the hazard ratios and 95% confidence intervals. Statistical analyses were performed using GraphPad Prism 5.0E (GraphPad Software Inc, La Jolla, CA, USA) or SPSS (SPSS Inc, Chicago, IL, USA). P values less than 0.05 were considered to be statistically significant.
Results

Clinical Characteristics of Patients With PH
Clinical characteristics of the 136 patients are shown in Table 1 . During the follow-up period of 53.5±4.5 months, 47 patients died of cardiovascular causes.
Current Therapies for PH
In the 136 patients with PH, 122 (90%) were treated with oral (n=71) or intravenous prostacyclin (n=51), 45 (33%) with bosentan, and 8 (6%) with sildenafil ( Table 1) . Although it has already been reported that monotherapy with intravenous epoprostenol or oral bosentan or sildenafil improves symptoms, 6-min walk distance, pulmonary hemodynamics, and survival in patients with PAH, 13-16 some of the present patients needed additional treatment. In particular, among the patients with PAH who did not respond to any monotherapy, combination therapy with oral or intravenous prostacyclin, 
Treatment
Oral prostacyclin, n (%) 71 (52%)
Values are mean ± SEM. PH, pulmonary hypertension; PAH, pulmonary arterial hypertension; PVOD, pulmonary veno-occlusive disease; CTEPH, chronic thromboembolic pulmonary hypertension.
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bosentan, and sildenafil significantly improved pulmonary hemodynamics ( Figure S3A-D) .
Biochemical Prognostic Factors
Of the complications in this group of PH patients, thyroid dysfunction was most the common (n=58, 46%), comprising hyperthyroidism in 11 (19%) and hypothyroidism in 47 (81%); 5 of the 11 patients with hyperthyroidism were treated with antithyroid drugs, and 3 of the 47 patients with hypothyroidism were treated with thyroid hormone replace- 
Treatment
Antithyroid drugs, n (% of hyperthyroidism) 5 (45%)
Thyroid hormone replacement, n (% of hypothyroidism) 3 (6%)
Abbreviation see in Table 1 . were treated for thyroid dysfunction, the plasma level of brain natriuretic peptide (BNP) was significantly higher during the period of thyroid dysfunction than during the euthyroid period. (B) There was no significant difference in the prognosis between the patients with thyroid dysfunction (n=58) and those without it (n=69). (C) When the patients were divided into 3 groups by plasma level of T3, the prognosis of the low T3 group (n=31) was significantly worse compared with the normal or increased T3 group (n=27) and the no thyroid dysfunction group (n=69).
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ment therapy ( Table 2 ). In the present study, 90% of the patients were treated with oral or intravenous prostacyclin ( Table 1) , and there was no significant difference in the prevalence of thyroid dysfunction between those treated with prostacyclin (55 of 116 patients, 47%) and those without it (3 of 11 patients, 27%). Interestingly, the prevalence of thyroid dysfunction was significantly higher in the patients with PAH than in those with CTEPH (Table 3) . Although the patients with thyroid dysfunction had higher plasma levels of BNP than those without it (450±120 vs 177±39 pg/ml, P<0.05) (Figure 1A) , thyroid dysfunction itself did not have a significant prognostic impact (Figure 1B) . However, the patients with low T3 levels had a significantly poor prognosis by univariate analysis (P<0.01, hazard ratio: 2.368, 95% confidence interval: 1.221-4.593) ( Figure 1C) .
An elevated plasma level of BNP, which indicates rightheart failure, was also a significant prognostic factor in the univariate analysis (P<0.001, hazard ratio: 3.609, 95% confidence interval: 1.856-7.016), whereas multivariate analysis demonstrated that BNP was a significant independent prognostic predictor in all PH patients ( Table 4) .
Hemodynamic Prognostic Factors
Hemodynamic parameters, such as CI at diagnosis, RAP and SV
• O2, which are established prognostic factors, were also significant prognostic factors in our univariate analysis, whereas mean PAP was not ( Table 4) .
Low CO at diagnosis was a poor prognostic factor for death within 1 year (Figure 2A, Table 4 ). Importantly, in the univariate analysis patients with low CO at diagnosis (CI <2.5, n=45) followed by subsequent CI normalization in response to treatment (CI ≥2.5, n=34) survived significantly longer than those who did not respond to the treatment (CI <2.5, n=11) ( Figure 2B, Table 4 ). However, among 43 patients with normal CI at diagnosis (CI ≥2.5), there were 37 with a subsequent normal CI (CI ≥2.5), of whom 29 survived and 8 died. Of the remaining 6 patients whose CI was reduced during the follow-up (CI <2.5), 5 survived and 1 died, indicating the insignificant difference in the CI response among patients with normal CI at the diagnosis.
Importantly, multivariate analysis demonstrated that among the significant prognostic factors in the univariate analysis, only CI improvement in response to treatment was an independent prognostic factor of PH in patients with low CI at diagnosis (Table 4) .
Furthermore, there were no significant differences in PH treatment between survivors and those who died, except for monotherapy with intravenous prostacyclin in all PH patients ( Table 5) .
Discussion
In the present study, we aimed to identify new prognostic factors of PH in a relatively large cohort of patients with a long-term close follow-up. The results suggest that CI PGI2 oral + sildenafil, n (%) 1 (3.0%) 0 (0%) NS 0 (0%) 0 (0%) -PGI2 intravenous + sildenafil, n (%) 0 (0%) 1 (12.5%) NS 0 (0%) 1 (50.0%) NS PGI2 oral+bosentan + sildenafil, n (%) 1 (3.0%) 0 (0%) NS 0 (0%) 0 (0%) -PGI2 intravenous + bosentan + sildenafil, n (%) 2 (6.1%) 1 (12.5%) NS 0 (0%) 0 (0%) -CCB, calcium-channel blocker; PGI2, prostaglandin I2. Other abbreviation see in Table 1 .
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normalization in response to treatment is a new prognostic factor of PH and probably has more prognostic significance than BNP and other previously established prognostic factors.
Cohort of PH Patients
Our cohort of PH had more female patients with a more prevalence of PH, and most of the patients were treated with prostacyclin alone or in combination with other vasodilators, a finding consistent with previous reports. 1,17-19 Our cohort is unique because all patients were closely followed by rightheart catheterization performed every 6-12 months in order to monitor their clinical course and to adjust the doses of drugs, including epoprostenol, bosentan and/or sildenafil. All of the drugs, especially the combination with intravenous prostacyclin and other vasodilators, have already been reported to improve symptoms, 6-min walk distance, pulmonary hemodynamics, and survival. 9,20-24 Indeed, in the present study, combination therapy with intravenous prostacyclin and other vasodilators significantly improved pulmonary hemodynamics in patients with PH who were not improved by any monotherapy. However, if combination therapy is unavailable, monotherapy with intravenous prostacyclin might not be enough in patients with severe PH, as shown in Table 5 .
Our current strategy for advanced PH is to improve quality of life and pulmonary hemodynamics (especially CI and RAP) and to prevent the development of right-heart failure, although more therapeutic progress needs to be made. [25] [26] [27] [28] [29] BNP Levels in PH Elevated BNP level is a significant prognostic factor, 10 but in the present study this was the case in the univariate analysis only, not in the multivariate analysis when we included the CI response to treatment. This result suggests that BNP and CI closely influence each other through right ventricular dysfunction and that the CI response has more prognostic significance than BNP. However, BNP should remain in use as a prognostic factor because it is easily and non-invasively measured.
Thyroid Dysfunction in PH
The present study demonstrated that 46% of the PH patients had thyroid dysfunction (hyperthyroidism in 19%; hypothyroidism in 81%). Indeed, 5 of 11 patients with hyperthyroidism were treated with antithyroid drugs, and 3 of 47 patients with hypothyroidism were treated with thyroid hormone replacement therapy, which is consistent with previous studies in which 22-49% of patients with PAH were complicated with thyroid dysfunction. 30, 31 The precise mechanisms of thyroid dysfunction in PH remain unclear; however, involvement of autoimmune mechanisms and the side-effects of prostacyclin therapy may be involved. 30 Indeed, it was reported that the treatment of thyroid dysfunction ameliorated PAP in PH patients complicated with thyroid diseases. 32-34 It also was reported that prostacyclin plays an important role in the modulation of thyroid function in patients with Graves disease, because prostacyclin therapy may cause thyrotoxicosis as a result of downregulation of prostaglandin I2 receptors, with subsequent reduced production of cAMP. 32, 33 However, in the present study, no significant influence of prostacyclin therapy was noted on the occurrence of thyroid dysfunction. Furthermore, a low plasma T3 level was a significant prognostic factor by univariate analysis but not by multivariate analysis. In contrast, a low plasma T3 level has been reported as associated with poor prognosis in patients with chronic heart failure. [35] [36] [37] Hemodynamic Variables in PH Although echocardiography is a non-invasive and useful tool for the follow-up of PH patients, because it can estimate systolic PAP, it alone is not enough to evaluate pulmonary hemodynamics, because RAP, SV
• O2 and CI are more important prognostic factors that cannot be obtained by echocardiography. 38-40 Therefore, right-heart catheterization is essential for both accurately evaluating pulmonary hemodynamics and decision making in each PH patient. 38-40 Indeed, low CO at diagnosis is a prognostic factor of PAH 41 and further, the present study demonstrated that CO normalization in response to treatment is a new prognostic factor.
During the course of the development of PAH, pulmonary arteriopathies first occur, followed by RV pressure-overload. Thus, the final goal of PH should be regression of pulmonary arteriopathies. 6 At present, because none of the available therapies is able to normalize pulmonary hemodynamics (especially during exercise), RV function (eg, CO) may determine the prognosis of PH patients. 41 
Study Limitations
Several limitations should be mentioned. First, this was an observational cohort study from a single center, so the present finding regarding the prognostic impact of CI normalization remain to be confirmed in a large, multicenter clinical study. Second, the PH patients were treated individually, but not in a randomized manner, based on their pulmonary hemodynamics and comorbidities, so some bias could be involved. However, considering the severity of the disease, such a randomized clinical study would not be appropriate from the ethical point of view.
Conclusions
In the present study, we were able to identify that CI normalization in response to treatment is a new independent prognostic factor of PH in patients with low CI at diagnosis, suggesting the importance of intensive therapy to normalize CO in PH patients.
